MA26908A1 - S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires - Google Patents

S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires

Info

Publication number
MA26908A1
MA26908A1 MA26927A MA26927A MA26908A1 MA 26908 A1 MA26908 A1 MA 26908A1 MA 26927 A MA26927 A MA 26927A MA 26927 A MA26927 A MA 26927A MA 26908 A1 MA26908 A1 MA 26908A1
Authority
MA
Morocco
Prior art keywords
ziprasidone
psychiatric
dihydro
methyl
treatment
Prior art date
Application number
MA26927A
Other languages
English (en)
Inventor
Aggarwal Prakash Chandra
Annette Smolarek Teresa
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26908(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26908A1 publication Critical patent/MA26908A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA26927A 2000-06-02 2002-11-29 S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires MA26908A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
MA26908A1 true MA26908A1 (fr) 2004-12-20

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26927A MA26908A1 (fr) 2000-06-02 2002-11-29 S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires

Country Status (44)

Country Link
US (1) US20060287336A1 (fr)
EP (3) EP1286672B1 (fr)
JP (2) JP2003534381A (fr)
KR (1) KR20030007824A (fr)
CN (1) CN1431901A (fr)
AP (2) AP1831A (fr)
AR (1) AR028937A1 (fr)
AT (3) ATE343387T1 (fr)
AU (1) AU2001258690A1 (fr)
BG (1) BG107267A (fr)
BR (1) BR0111271A (fr)
CA (1) CA2410618A1 (fr)
CY (1) CY1105992T1 (fr)
CZ (1) CZ20023860A3 (fr)
DE (3) DE60124791T2 (fr)
DK (1) DK1468686T3 (fr)
DO (1) DOP2001000181A (fr)
EA (1) EA007068B1 (fr)
EC (1) ECSP024369A (fr)
EE (1) EE200200670A (fr)
ES (1) ES2277170T3 (fr)
GE (1) GEP20053512B (fr)
HN (1) HN2001000119A (fr)
HR (1) HRP20020953A2 (fr)
HU (1) HUP0301747A2 (fr)
IL (2) IL152782A0 (fr)
IS (1) IS6619A (fr)
MA (1) MA26908A1 (fr)
MX (1) MXPA02011862A (fr)
NO (1) NO325077B1 (fr)
NZ (1) NZ551012A (fr)
OA (1) OA12267A (fr)
PA (1) PA8518301A1 (fr)
PE (1) PE20011329A1 (fr)
PL (1) PL365576A1 (fr)
PT (2) PT1468686E (fr)
SI (1) SI1468686T1 (fr)
SK (1) SK16622002A3 (fr)
SV (1) SV2002000473A (fr)
UA (1) UA79425C2 (fr)
UY (1) UY26742A1 (fr)
WO (1) WO2001091756A2 (fr)
YU (1) YU90702A (fr)
ZA (1) ZA200209665B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296991A1 (en) 2002-12-13 2004-07-09 Regents Of The University Of Minnesota Scleral depressor
CA2543805A1 (fr) 2003-10-24 2005-05-06 Gideon Pilarsky Procedes de preparation de ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
US6110918A (en) * 1996-05-07 2000-08-29 Pfizer Inc Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
ATE247963T1 (de) * 1998-05-26 2003-09-15 Pfizer Prod Inc Medikament zur behandlung von glaukoma und ischämischer retinopathie
WO2000059489A2 (fr) * 1999-04-06 2000-10-12 Sepracor Inc. Methodes et compositions pour le traitement des troubles neuroleptiques et associes au moyen de metabolites de ziprasidone

Also Published As

Publication number Publication date
CA2410618A1 (fr) 2001-12-06
HRP20020953A2 (en) 2005-02-28
DE60124093D1 (de) 2006-12-07
AP1747A (en) 2007-05-31
SK16622002A3 (sk) 2004-07-07
UY26742A1 (es) 2001-12-28
DOP2001000181A (es) 2002-04-15
IL152782A0 (en) 2003-06-24
EP1698338A3 (fr) 2006-09-20
NO325077B1 (no) 2008-01-28
ES2277170T3 (es) 2007-07-01
AR028937A1 (es) 2003-05-28
NZ551012A (en) 2008-04-30
OA12267A (en) 2004-01-20
EP1286672B1 (fr) 2006-10-25
YU90702A (sh) 2005-11-28
DK1468686T3 (da) 2007-03-12
MXPA02011862A (es) 2003-04-10
ECSP024369A (es) 2003-02-06
WO2001091756A2 (fr) 2001-12-06
PE20011329A1 (es) 2002-01-15
CN1431901A (zh) 2003-07-23
ATE345818T1 (de) 2006-12-15
EP1468686B1 (fr) 2006-11-22
ATE343387T1 (de) 2006-11-15
GEP20053512B (en) 2005-05-10
AU2001258690A1 (en) 2001-12-11
JP2003534381A (ja) 2003-11-18
CY1105992T1 (el) 2011-04-06
EP1698338B1 (fr) 2008-04-09
EE200200670A (et) 2004-08-16
US20060287336A1 (en) 2006-12-21
EP1286672A2 (fr) 2003-03-05
PL365576A1 (en) 2005-01-10
KR20030007824A (ko) 2003-01-23
UA79425C2 (en) 2007-06-25
NO20025760D0 (no) 2002-11-29
DE60133596D1 (de) 2008-05-21
IL152782A (en) 2007-10-31
SV2002000473A (es) 2002-10-24
EP1698338A2 (fr) 2006-09-06
HN2001000119A (es) 2001-09-11
SI1468686T1 (sl) 2007-04-30
ATE391507T1 (de) 2008-04-15
EA200201168A1 (ru) 2003-06-26
NO20025760L (no) 2003-01-15
WO2001091756A3 (fr) 2002-09-26
EA007068B1 (ru) 2006-06-30
DE60124791D1 (de) 2007-01-04
PT1698338E (pt) 2008-06-03
JP2008056700A (ja) 2008-03-13
DE60124791T2 (de) 2007-09-13
BG107267A (bg) 2003-06-30
EP1468686A3 (fr) 2004-12-01
CZ20023860A3 (cs) 2004-01-14
EP1468686A2 (fr) 2004-10-20
ZA200209665B (en) 2003-11-28
PA8518301A1 (es) 2002-09-17
AP1831A (en) 2008-02-26
HUP0301747A2 (hu) 2003-09-29
AP2005003272A0 (en) 2005-03-31
PT1468686E (pt) 2007-01-31
BR0111271A (pt) 2003-06-10
IS6619A (is) 2002-11-14

Similar Documents

Publication Publication Date Title
EP1237625A4 (fr) Dispositif d'illumination pour traitement d'atteintes oculaires
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1357908A4 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
FR2785521B1 (fr) Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP1067940A4 (fr) Facteurs associes a l'asthme servant de cibles pour le traitement d'allergies atopiques dont l'asthme et des troubles associes
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
FR2816513B1 (fr) Valve sous-cutanee pour le traitement de l'hydrocephalie et ses dispositifs de reglage
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
EP1575577A4 (fr) Composition pour la prevention et le traitement de l'inflammation de l'oreille
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1305015A4 (fr) Styryl benzylsulfones substitues pour le traitement de troubles proliferatifs
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP1830873A4 (fr) Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques
EP1448193A4 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
EP1058546A4 (fr) Traitement de troubles maculaires et composition appropriee